Announcement from CTF.org:
The NF Preclinical Consortium (NFPC) is a multi-site collaboration of six research Centers for Phase 1 (2007-2011). Each is focused on different tumor manifestations of NF1 and NF2. The two NF2 centers are:
- Harvard Med School/Mass General Hospital, Director: Andrea McClatchey, Ph.D.
- House Ear Institute, Director: Marco Giovannini, MD, Ph.D. Tumor Focus at both: NF2 schwannoma, meningioma
The Drug Discovery Initiative (DDI) is a new program by the Children’s Tumor Foundation (CTF) aimed at diversifying and increasing the pipeline of drugs that are tested in the NFs, via preclinical models.